预后营养指数评估小细胞肺癌患者预后的临床价值

承德医学院学报 ›› 2019, Vol. 36 ›› Issue (5): 393-397.

预后营养指数评估小细胞肺癌患者预后的临床价值

薛晶雯¹, 王又君¹, 郭静¹, 张金洋¹, 吕喜英^2△

1.承德医学院,河北承德 067000;
2.承德医学院附属医院肿瘤科

收稿日期:2019-04-10 出版日期:2019-10-10 发布日期:2021-11-18
通讯作者: △

Received:2019-04-10 Online:2019-10-10 Published:2021-11-18

摘要/Abstract

摘要： 目的:探讨预后营养指数（PNI）评估小细胞肺癌（SCLC）患者预后的临床价值。方法:回顾性分析261例SCLC患者的临床资料,通过绘制受试者工作特征（ROC）曲线确定PNI最佳截断值,根据最佳截断值将患者分为高PNI组和低PNI组,并采用Cox比例风险模型分析影响SCLC患者预后的因素。结果:SCLC患者根据PNI值分为低PNI组（<48.9）和高PNI（≥48.9）组;低PNI组（153例）中位总生存期13.0个月,高PNI组（108例）中位总生存期26.0个月。单因素分析中,吸烟指数、临床分期、PNI值及治疗方式与患者预后相关;多因素分析显示,吸烟指数、临床分期、PNI及治疗方式是总生存期的独立危险因素（P<0.01）。结论:PNI可作为评估SCLC患者预后的独立危险因素。

关键词: 预后营养指数（PNI）, 小细胞肺癌（SCLC）, 危险因素, 预后评估

中图分类号:

R734.2

薛晶雯, 王又君, 郭静, 张金洋, 吕喜英. 预后营养指数评估小细胞肺癌患者预后的临床价值[J]. 承德医学院学报, 2019, 36(5): 393-397.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] PASTORE C A, ORLANDI S P, GONZALEZ M C.The Inflammatory-Nutritional Index; assessing nutritional status and prognosis in gastrointestinal and lung cancer patients[J]. Nutr Hosp, 2014, 29(3): 629-634.
[3] ONODERA T, GOSEKI N, KOSAKI G.Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients[J]. Nihon Geka Gakkai Zasshi, 1984,85(9):1001-1005.
[4] YAO Z H, TIAN G Y, WAN Y Y, et al.Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma[J]. J Cancer Res Clin Oncol, 2013, 139(12): 2117-2123.
[5] 许文娟,康妍萌,周玲,等.预后营养指数评估中晚期非小细胞肺癌患者预后的临床应用价值[J].中华肿瘤杂志,2017,39(2):146-149.
[6] van MEERBEECK J P, FENNELL D A, De RUYSSCHER D K. Small-cell lung cancer[J]. Lancet, 2011, 378(9804): 1741-1755.
[7] MIGITA K, TAKAYAMA T, SAEKI K, et al.The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage[J]. Ann Surg Oncol, 2013, 20(8): 2647-2654.
[8] MANTOVANI A, ALLAVENA P, SICA A, et al.Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444.
[9] CÉZÉ N, THIBAULT G, GOUJON G, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy[J]. Cancer Chemother Pharmacol, 2011, 68(5): 1305-1313.
[10] PROCTOR M J, MORRISON D S, TALWAR D, et al.A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study[J]. Eur J Cancer, 2011, 47(17): 2633-2641.
[11] LIN P H, ARONSON W, FREEDLAND S J.Nutrition, dietary interventions and prostate cancer: the latest evidence[J]. BMC Med, 2015, 13: 3.
[12] SHIMIZU K, OKITA R, SAISHO S, et al.Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer[J]. World J Surg Oncol, 2015, 13: 291.
[13] MEONI G, CECERE F L, LUCHERINI E, et al.Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents[J]. J Geriatr Oncol, 2013, 4(3): 282-290.
[14] HSU C L, CHEN J H, CHEN K Y, et al.Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis[J]. J Geriatr Oncol, 2015, 6(1): 38-45.